A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, 4‐Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants

Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, is approved (United States and European Union; Sunosi) to treat excessive daytime sleepiness associated with narcolepsy (75‐150 mg/day) or obstructive sleep apnea (37.5‐150 mg/day). A thorough QT/QTc study assessed solriamfetol effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Zomorodi, Katie, Chen, Dan, Lee, Lawrence, Swearingen, Dennis, Carter, Lawrence P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048583/
https://www.ncbi.nlm.nih.gov/pubmed/32935460
http://dx.doi.org/10.1002/cpdd.867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048583/
https://www.ncbi.nlm.nih.gov/pubmed/32935460
http://dx.doi.org/10.1002/cpdd.867

Ejemplares similares